InfliximabadalimumabIBDinflammatory bowel disease
…faecal calprotectin (r = –0.10, p = 0.62) were not significant. Infliximab cohort: 145 patients (420 determinations), mean age 47 ± 20 yea…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 781–840 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
RASI4bisphosphonate4Ivonescimab4VDZ4IABP4WEB4Edaravone4Fenfluramine4PEG-IFN4Tadalafil4BDP/FF/G4Eltrombopag4THC4Adagrasib4Contour4Formaldehyde4Mosunetuzumab4TDF4TP4Tralokinumab4riociguat4Mirikizumab4PDE5i4Tobramycin4leptin4ACEI4EmboTrap4Palonosetron4glargine4177Lu4AIR4Brainomix4Desmopressin4Indomethacin4NT-pro BNP4risedronate4Adiponectin4Aldesleukin4HTPs4IL-214NSBBs4angiotensin converting enzyme inhibitors4cortisol4sodium valproate4ADU-S1004CLDN18.24Clavien-Dindo4Cytisine4FFP4Glofitamab4Perineural dexamethasone4TAC4TGFβ14Talquetamab4amoxicillin-clavulanic acid4buprenorphine/naloxone4eptifibatide40.25% ropivacaine4Antithrombotics4ERA4
Articles mentioning drugs
10,506 articles · page 137 of 876pembrolizumabrenal cancernon-small-cell lung cancermelanomabreast cancercolorectal cancercervical cancerhead and neck cancergastric cancerendometrial cancer
… from €18 to €14,567. By cancer type, the patients treated with pembrolizumab 2 mg/kg included: 16 with head and neck cancer, nine with cervi…
ceftazidime-avibactam-aztreonamCeftazidimeaztreonamaztreonam-avibactamAvibactamMBL-producing EnterobacteriaceaeMBL-producing infectionsSepsisinfections
…CI. Analysis: M365 Copilot.Results Eight-four patients received ceftazidime-avibactam-aztreonam.Abstract 4CPS-113 Table 1Sociodemographic profileMale gender 61…
zonisamiderimegepanttopiramateamitriptylineflunarizineVisual Analogue Scaletertiary-care hospitalmigraine
…riptyline (89.1%), flunarizine (78.3%), topiramate (76.1%), and zonisamide (50.0%). Prior biologic therapy included three agents in 13.0% …
pembrolizumabpembrolizumab-chemotherapydoxorubicincarboplatinpaclitaxelcyclophosphamideTriple-negative breast cancer (TNBC)neoadjuvant chemotherapyTNBC
…and poor prognosis. Adding immune checkpoint inhibitors such as pembrolizumab to neoadjuvant chemotherapy has improved pathological response …
pembrolizumabdurvalumabdostarlimabtremelimumabnivolumabatezolizumabcemiplimabavelumabipilimumabimmunotherapy+2 more
…Results In 2023 and 2024 we used seven immunotherapeutic drugs: pembrolizumab (230 patients), durvalumab (45 patients), atezolizumab (45 pati…
CLARclarithromycinpneumoniaMerckpulmonology departmentICU
…0 ml/min) increased serum levels for all administration routes. CLAR serum levels increased proportionally with increasing albumin s…
ceftriaxonemeropenemmetronidazolepiperacillin/tazobactamvancomycintertiary hospitaltherapeutic de-escalationtherapeutic escalationantimicrobial resistancetreatment discontinuation+1 more
…18%), meropenem (16.8%), and metronidazole (12.4%), followed by ceftriaxone (9.1%).In 2024, 44 meetings were held, reviewing 185 treatments…
colistinenystatintobramycinONArecurrent cholangitisthird-degree hospitalcholangitis
…t symptom onset. However, oral nonabsorbable antibiotics (ONA) (colistine, nystatin and tobramycin in suspension) constitute an alternati…
Afliberceptranibizumabage-related macular degeneration (ARMD)ARMDRetinal diseases
…naïve patients experienced modest improvement in visual acuity. Aflibercept enabled extended injection intervals in both groups, particular…
tezepelumabasthma
…, and 21% three biological drugs.Before starting treatment with tezepelumab, 89% of patients received oral corticosteroids (OCS) as mainten…
defibrotideGemtuzumabInotuzumabgemtuzumab ozogamicinadrenoleukodystrophyneuroblastomaSOSAMLSinusoidal obstruction syndrome (SOS)
…ary paediatric hospital, who met SOS risk criteria and received defibrotide prophylaxis.Material and Methods Retrospective cohort of paedia…